Oral contraceptives containing drospirenone may be associated with a higher risk of venous thromboembolism (VTE) than birth control pills without this ingredient, according to a US Food and Drug Administration (FDA) safety update.
The FDA issued the update in late September to alert the public that preliminary results from an agency study found a 1.5-fold increase in VTE among women taking oral contraceptives containing drospirenone compared with users of other hormonal contraceptives (http://www.fda.gov/Drugs/DrugSafety/ucm273021.htm). Previously, the agency had announced it was evaluating conflicting data on whether a higher risk of VTE was associated with drospirenone use compared with use of birth control pills containing levonorgestrel or other progestins.
Kuehn BM. Blood Clot Risk. JAMA. 2011;306(16):1750. doi:10.1001/jama.2011.1538
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: